drugset
drugset / Trial / NCT00004078

Irinotecan in Treating Children With Refractory Solid Tumors

NCT00004078 ↗

Phase 2 Completed 181 enrolled Children's Oncology Group National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying irinotecan to see how well it works in treating children with refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Timeline

Start
1999-10
Primary completion
2007-10
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule — Intravenous

Indications

Ewing sarcoma/peripheral primitive neuroectodermal tumor benign meningioma cerebellar astrocytoma childhood central nervous system germ cell tumor childhood cerebral astrocytoma childhood choroid plexus neoplasm childhood medulloblastoma childhood oligodendroglioma craniopharyngioma grade II meningioma grade III meningioma neuroblastoma optic pathway glioma osteosarcoma pediatric infratentorial ependymoma pediatric supratentorial ependymoma rhabdomyosarcoma